Literature DB >> 31038158

Prospective evaluation of a rapid antimicrobial susceptibility test (QMAC-dRAST) for selecting optimal targeted antibiotics in positive blood culture.

Jeong-Han Kim1, Taek Soo Kim2, Hyun Gul Jung1, Chang Kyung Kang1, Kang-Il Jun1, Sangkwon Han3, Dong Young Kim3, Sunghoon Kwon3, Kyoung-Ho Song1, Pyeong Gyun Choe1, Ji Hwan Bang1, Eu Suk Kim1, Sang Won Park1, Hong Bin Kim1, Nam Joong Kim1, Wan Beom Park1, Myoung-Don Oh1.   

Abstract

OBJECTIVES: MALDI-TOF MS has been successfully used for empirical antibiotic selection. However, limited data are available regarding the usefulness of MALDI-TOF MS in common resistant organisms compared with rapid antimicrobial susceptibility testing (AST). We prospectively evaluated the usefulness of rapid AST, compared with MALDI-TOF MS, for optimal antibiotic selection by infectious disease (ID) physicians in patients with bacteraemia including polymicrobial infection.
METHODS: Three hundred and fifty-nine patients with positive blood culture were included for analysis. ID physicians prospectively decided on antibiotic regimens with consensus at each timepoint of receiving results of Gram stain, MALDI-TOF MS and rapid AST, the last of which was performed using QMAC-dRAST.
RESULTS: ID physicians with MALDI-TOF MS results chose optimal targeted antibiotics in 255 (71.0%) cases, with appropriate antibiotic selection in 303 (84.4%) cases. The proportion of optimal targeted antibiotic selection and appropriate antibiotic selection was significantly lower for resistant strains than for susceptible strains [62.5% versus 79.2% (P < 0.001) and 68.2% versus 100% (P < 0.001), respectively]. QMAC-dRAST results led to optimal antibiotic treatment in 95 (91.3%) of the 104 cases receiving non-optimal targeted antibiotics. Optimal targeted treatments based on QMAC-dRAST results were possible in 322 (98.2%) of the 328 cases with monobacterial infection and in 345 (96.1%) of the 359 cases with monobacterial and polymicrobial infection.
CONCLUSIONS: MALDI-TOF MS has a high chance of failure in guiding ID physicians to optimal antibiotics, especially against resistant organisms. With increasingly common resistant organisms, rapid AST is needed to identify optimal targeted antibiotics early in bacteraemia.
© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Year:  2019        PMID: 31038158     DOI: 10.1093/jac/dkz168

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

Review 1.  Innovative and rapid antimicrobial susceptibility testing systems.

Authors:  Alex van Belkum; Carey-Ann D Burnham; John W A Rossen; Frederic Mallard; Olivier Rochas; William Michael Dunne
Journal:  Nat Rev Microbiol       Date:  2020-02-13       Impact factor: 60.633

2.  A Direct Rapid Phenotypic Antimicrobial Susceptibility Test Enables Early Selection of Optimal Antibiotics to Treat Bacteremia in COVID-19 Patients.

Authors:  Taek Soo Kim; Wan Beom Park; Do Hyeon Park; Euijin Chang; Chang Kyung Kang; Pyoeng Gyun Choe; Nam Joong Kim; Myoung-Don Oh
Journal:  Infect Chemother       Date:  2021-12

3.  Risk factors for and clinical outcomes of carbapenem non-susceptible gram negative bacilli bacteremia in patients with acute myelogenous leukemia.

Authors:  Dong Hoon Shin; Dong-Yeop Shin; Chang Kyung Kang; Suhyeon Park; Jieun Park; Kang Il Jun; Taek Soo Kim; Youngil Koh; Jun Shik Hong; Pyoeng Gyun Choe; Wan Beom Park; Nam-Joong Kim; Sung-Soo Yoon; Inho Kim; Myoung-Don Oh
Journal:  BMC Infect Dis       Date:  2020-06-09       Impact factor: 3.090

4.  Real Life Clinical Impact of Antimicrobial Stewardship Actions on the Blood Culture Workflow from a Microbiology Laboratory.

Authors:  Jose Maria López-Pintor; Javier Sánchez-López; Carolina Navarro-San Francisco; Ana Maria Sánchez-Díaz; Elena Loza; Rafael Cantón
Journal:  Antibiotics (Basel)       Date:  2021-12-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.